[PDF] Top 20 New developments in intrauterine device use: focus on the US
Has 10000 "New developments in intrauterine device use: focus on the US" found on our website. Below are the top 20 most common "New developments in intrauterine device use: focus on the US".
New developments in intrauterine device use: focus on the US
... There are two significant differences between these two higher-dose LNG-releasing IUDs: the systems used to place the IUD into the uterine cavity and the price of the IUDs. Both of the LNG-IUSs now use single ... See full document
15
New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
... EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit ... See full document
7
New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel
... Treatment of AK is managed with lesion-directed and field- directed methods, and frequently multiple methods are selected based on the characteristics of the lesions, overall sun damage, and the patient’s ability to ... See full document
12
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
... maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single ... See full document
8
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
... sequential use of third-generation EGFR-TKIs, recent data showed that two of four patients with progression after roci- letinib experienced a prolonged stabilization of their disease (for more than 200 days) with ... See full document
10
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
... with adalimumab, and 80% of those treated with infliximab (Table 1). It is also worth noting that emerging biological therapies are proving to be effective. Anti-IL-17 therapies see 75%–86% of psoriasis patients reach ... See full document
10
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
... of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug ...the use of trastuzumab in advanced gastric ... See full document
6
New developments in treatment of ovarian carcinoma: focus on trabectedin
... Abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Trabectedin has shown promising single-agent activity in pretreated ... See full document
10
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
... Botulinum toxin comprises seven subtypes, of which subtype A (botulinum toxin A), which has the longest dura- tion of action, is clinically the most important. Botulinum toxin A is available in three different commercial ... See full document
10
New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
... opioid use; the retention rate seems to be somewhat lower with BUP, but the long-term mortality risk may also be ...may focus in particular on the effects of BUP on psychiatric aspects or psychiatric ... See full document
14
New developments in the treatment of osteoarthritis – focus on biologic agents
... to focus on finding the best treatment option, to eradicate and stop this degenerative joint disease, in order to avoid surgical options which in many instances are ...The use of PRP has led to many ... See full document
11
New developments in the clinical use of drug-coated balloon catheters in peripheral arterial disease
... of these authors that future studies should prioritize these clinical end points to help differentiate efficacy. At the same time, the pilot registry and DEBATE-BTK studies suggest that DCB-treated lesions may ... See full document
14
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
... depends on the patient’s clinical condition. The devices cur- rently in use are varied. In particular, there are metered-dose inhaler (MDI) devices on one side and DPI devices on the other. The first are spray or ... See full document
9
Use and discontinuation of intrauterine contraceptive device in the Greater Accra Region of Ghana
... The women in the study (a sample predisposed to knowing about FP by having visited a FP clinic before) knew of at least one modern method. This finding is consistent with previous findings in Ghana’s Demo- graphic and ... See full document
17
Evaluation of safety, efficacy and expulsion of post placental insertion of intrauterine contraceptive device
... 21. O’hanley K, Huber Dh April 2007, New York. Insertion at immediate postplacental and postpartum periods are demonstrably safe, because they have a low incidence of infection, few bleeding problems, and low ... See full document
140
Intrauterine Device Use in Adolescents With Disabilities
... for use in this population for multiple ...of use for the 52-mg levonorgestrel IUD (Mirena), although a newer 52-mg levonorgestrel IUD (Liletta) is approved for 6 years, and there are data that support ef fi ... See full document
10
Intrauterine device quo vadis? Why intrauterine device use should be revisited particularly in nulliparous women?
... study new IUD methods as those described in this article, and compare them with existing birth control methods, in adolescent and young women for interval, postcoital, and ... See full document
12
Intrauterine Contraceptive Device Use in Port Harcourt, Southern Nigeria: A Retrospective Analysis
... The IUCD acceptance rate of 25.5% among new acceptors of contraception is higher than the 16.2% uptake rate [12] previously reported in Port Harcourt, but lower than prevalence rates reported earlier in other ... See full document
8
New developments in the use of prostatic stents
... New technologies are promising to alleviate some of the concerns regarding the use of prostatic stents, such as migration and encrustation. It is hoped that temporary bio- degradable stents as well as ... See full document
6
<p>Asherman’s syndrome: current perspectives on diagnosis and management</p>
... Abstract: Intrauterine adhesions with symptoms like hypomenorrhea or infertility are known under the term Asherman’s ...of intrauterine adherences is necessary for the prevention of the formation of ... See full document
8
Related subjects